Market closed
Geron/$GERN
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Geron
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
Ticker
$GERN
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
141
Website
Geron Metrics
BasicAdvanced
$2.2B
Market cap
-
P/E ratio
-$0.32
EPS
0.51
Beta
-
Dividend rate
Price and volume
Market cap
$2.2B
Beta
0.51
52-week high
$5.34
52-week low
$1.64
Average daily volume
8.9M
Financial strength
Current ratio
2.886
Quick ratio
2.477
Long term debt to equity
5.041
Total debt to equity
5.041
Interest coverage (TTM)
-17.16%
Management effectiveness
Return on assets (TTM)
-30.30%
Return on equity (TTM)
-69.03%
Valuation
Price to revenue (TTM)
78.063
Price to book
7.55
Price to tangible book (TTM)
7.55
Price to free cash flow (TTM)
-10.63
Growth
Revenue change (TTM)
9,199.68%
Earnings per share change (TTM)
-5.33%
3-year revenue growth (CAGR)
318.22%
3-year earnings per share growth (CAGR)
-1.25%
What the Analysts think about Geron
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Geron stock.
Geron Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Geron Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Geron News
AllArticlesVideos
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·2 days ago
Geron Announces Positive CHMP Opinion for RYTELO™ (imetelstat) for the Treatment of Adults with Transfusion-Dependent Anemia due to Lower-Risk MDS
Business Wire·1 week ago
Geron to Participate in the 7th Annual Evercore ISI HealthCONx Conference
Business Wire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Geron stock?
Geron (GERN) has a market cap of $2.2B as of December 21, 2024.
What is the P/E ratio for Geron stock?
The price to earnings (P/E) ratio for Geron (GERN) stock is 0 as of December 21, 2024.
Does Geron stock pay dividends?
No, Geron (GERN) stock does not pay dividends to its shareholders as of December 21, 2024.
When is the next Geron dividend payment date?
Geron (GERN) stock does not pay dividends to its shareholders.
What is the beta indicator for Geron?
Geron (GERN) has a beta rating of 0.51. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.